Alfasigma Invests MX$100 Million to Expand OTC Business in Mexico

Italian pharmaceutical company Alfasigma will invest MX$100 million (US$5 million) to launch a new over-the-counter (OTC) business unit in Mexico. The expansion marks a significant step in the company’s regional strategy and highlights the growing importance of the Mexican market within its global operations.

The investment will focus on building the new unit’s infrastructure, including hiring personnel and launching promotional campaigns. It does not cover inventory procurement. The company plans to introduce three new gastrointestinal-focused OTC products before the end of the year.

“We believe we have an ideal portfolio for Mexican consumers,” says Vicenzo D’Elia, General Manager, Alfasigma, to Imagen Radio.

Headquartered in Italy, Alfasigma operates six pharmaceutical plants — four in Italy, one in the United States, and one in Spain. In Mexico, the company imports and commercializes its products locally, explains D’Elia. Since opening its Mexican subsidiary 15 years ago, Alfasigma has experienced a cumulative growth of 32%.

Recent currency stability between the Mexican peso and the euro exceeded the company’s initial expectations, influencing the decision to proceed with this investment. “This is good news for Mexican consumers and gives us greater certainty about our path forward,” says D’Elia.

Despite a challenging global environment, Alfasigma plans to keep investing in Mexico to position the country not only as a strategic market but also as a hub for talent development and regional expansion across Latin America. “Our mission in Mexico centers around delivering innovative, quality products to enhance the health and quality of life of Mexicans,” says D’Elia to MBN. “We also see Mexico as a pivotal platform to expand across Latin America.”

According to D’Elia, Mexico’s well-established pharmaceutical infrastructure, skilled workforce, and strategic location make it an ideal base for further innovation and regional growth.